Core Viewpoint - Fab-Form Industries Ltd. has been granted U.S. Patent No. 12,571,221 for its innovative adjustable footing bracket system, which enhances the efficiency of concrete construction by allowing contractors to quickly level and support foundation forms [1][3]. Patent Details - The patent covers a length-adjustable assembly that includes telescoping members and a threaded adjustment mechanism, enabling precise vertical positioning of concrete formwork [2]. - This design allows for rapid adjustments using common tools, improving installation speed, accuracy, and ease [2]. Company Impact - The patent is a significant milestone for Fab-Form, reinforcing its commitment to developing efficient and sustainable foundation systems for the construction industry [3]. - The patented technology aims to reduce labor time, enhance accuracy in foundation elevation, and minimize material waste on construction sites [2][4]. Intellectual Property and Market Position - The patent strengthens Fab-Form's intellectual property portfolio, enhancing its ability to commercialize innovative forming systems in both residential and commercial construction markets [4]. - Fab-Form has been trading on the TSX Venture Exchange under the symbol FBF since 2000, indicating its established presence in the market [5].

Core Insights - Tersis Technologies, Inc. has appointed Kevin H. Fortin as Vice President of Intellectual Property & Licensing to enhance its patent protection initiatives and develop high-margin licensing revenue streams [1][2]. Group 1: Appointment and Role - Kevin H. Fortin is a registered U.S. Patent Attorney with over 30 years of experience in managing global patent portfolios and executing multi-million-dollar licensing programs [2][5]. - His appointment signifies Tersis' transition from a technology development organization to a fully integrated platform focused on scalable deployment and long-term value creation [2][6]. Group 2: Strategic Importance - The company aims to build a competitive moat around its materials conversion and energy generation technologies, with Mr. Fortin's expertise in patent strategy and monetization being crucial for protecting innovations globally [4][6]. - Establishing a comprehensive intellectual property framework is deemed critical as Tersis scales its modular waste-to-value and energy infrastructure platforms [6]. Group 3: Leadership and Experience - Mr. Fortin has previously served as Senior Counsel at Philips Electronics, where he managed global patent licensing initiatives and developed enforcement strategies for high-value technology assets [5]. - He currently leads the Fortin Patent Firm, advising innovators on building defensible patent positions and converting intellectual property into recurring revenue streams [5]. Group 4: Company Overview - Tersis Technologies focuses on developing advanced materials conversion and clean energy infrastructure solutions that transform waste streams into valuable outputs such as electricity and hydrogen [7]. - The company is building a scalable platform through modular systems and strategic partnerships aimed at supporting sustainable infrastructure growth and long-term economic value creation [7].

Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce that the US Patent Office has issued Patent No. 12,570,656 B2 for MB-204 granting broad composition of matter and methods of use claims titled "Purine Compounds for Treati ...

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved therapies Patent protection extends into 2038 QTORIN™ rapamycin has previously been granted European Orphan Drug Designation for the treatment of microcystic lymphatic malformations, potentially providing 10 years of market exclusivity in the European Union upon approval Th ...

Summary of IP Strategy Holdings FY Conference Call Company Overview - **Company Name**: IP Strategy Holdings (NasdaqCM:IPST) - **Core Business**: The company is the first Nasdaq-listed entity to hold the IP token as its primary reserve asset and operates a validator on the Story Protocol, which is focused on intellectual property (IP) protection through tokenization [1][4][6]. Industry Context - **Industry Focus**: The discussion centers around the intellectual property sector, particularly in the context of challenges posed by AI and large language models (LLMs) that utilize copyrighted material without permission [4][15]. - **Market Size**: The intellectual property asset class is valued at approximately $80 trillion, indicating significant potential for blockchain applications in this area [15]. Key Points and Arguments - **Tokenization and IP Protection**: The Story Protocol is designed specifically for IP protection, allowing creators to register their works on-chain, set usage parameters, and ensure they are compensated for their creations [16][22]. - **Revenue Generation**: IP Strategy Holdings generates revenue through staking its IP tokens, with yields ranging from 10% to 20% annually. Additionally, a covered call strategy has yielded around 60% per year [11][36]. - **Acquisition Strategy**: The company is exploring the acquisition of IP-based assets, such as music catalogs and user-generated content, to enhance its portfolio and create a flywheel effect in the ecosystem [7][44]. - **Blockchain Advantages**: The Story Layer 1 blockchain is purpose-built for IP, allowing for efficient tracking and monetization of digital content, which is more effective than traditional methods [32][16]. Additional Insights - **Emerging Use Cases**: The ease of engaging with IP through blockchain is expected to stimulate new use cases, enabling everyday creators to interact with global IP more effectively [17]. - **Regulatory Environment**: The ongoing discussions in U.S. policy regarding the tokenization of assets may lead to a more favorable environment for blockchain applications in IP [56]. - **Competitive Landscape**: The company believes that the Story Protocol has the potential to become the industry standard for IP tokenization, supported by significant investments from major players in the field [30]. Conclusion - **Growth Potential**: IP Strategy Holdings is positioned for growth within the blockchain and IP sectors, leveraging its unique business model and the increasing importance of IP rights in the digital age [64].

Core Viewpoint - The U.S. International Trade Commission (ITC) has upheld GoPro's patent claim against Insta360, preventing the importation of Insta360's infringing products, thereby reinforcing GoPro's intellectual property rights and market position [1]. Group 1: Patent Infringement Ruling - The ITC confirmed that Insta360's action camera products infringe on GoPro's design patent for the HERO camera [1]. - A Limited Exclusion Order was issued to U.S. Customs and Border Protection to stop further importation of Insta360's infringing products [1]. - A Cease and Desist Order was also issued to Insta360, prohibiting the importation, sale, and marketing of the infringing products [1]. Group 2: Intellectual Property Enforcement - The ITC's ruling follows positive decisions from the Patent Trial and Appeal Board (PTAB) that upheld the validity of multiple GoPro utility patents [1]. - The PTAB rejected three challenges from Insta360 regarding patents covering GoPro's HyperSmooth technology [1]. - GoPro's intellectual property enforcement campaign highlights the strength of its portfolio, which includes over 1,500 U.S. patents [1]. Group 3: Company Statement and Innovation - GoPro's CEO emphasized the importance of innovation and the need to protect intellectual property to ensure original ideas are not imitated [1]. - The company aims to continue delivering industry-leading experiences by safeguarding its innovations [1].

Core Insights - Silo Pharma, Inc. has received a Notice of Allowance from the Japan Patent Office for a patent application related to its lead asset, SPC-15, which targets Post-Traumatic Stress Disorder (PTSD) [1][2][3] - The patent application is titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," enhancing Silo's intellectual property portfolio in stress-modulating therapeutics [2][3] - The approval of the patent is significant for Silo as it protects its lead asset and reinforces the novelty of its approach to preventing stress-induced behavioral disorders [3] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical company focused on innovative formulations and drug delivery systems for traditional therapeutics and psychedelic treatments [1][4] - The company addresses underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with a portfolio that includes SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain [4] - Silo conducts research in collaboration with leading universities and laboratories, indicating a strong foundation for its therapeutic developments [4]

Core Insights - Devonian Health Group Inc. has filed a proprietary Thykamine™ fingerprint in recent patent applications, which is a key element of its long-term intellectual property strategy [1] - The Thykamine™ fingerprint identifies eight specific chemical components in precise ratios, validated through advanced HPLC-MS methods, showing 98% confidence in batch consistency [1] - The company emphasizes the quality and consistency of Thykamine™, which has demonstrated anti-inflammatory and anti-fibrotic properties in various studies, including a Phase IIa clinical study [1] Patent Strategy - The Thykamine™ fingerprint will be systematically included in all future patent filings related to Thykamine™ [1] - This strategy aims to strengthen the company's intellectual property portfolio and regulatory preparedness for pharmaceutical development [1] Manufacturing and Quality Control - HPLC-MS methodology has shown high reproducibility across manufactured batches, confirmed by NMR analysis [1] - Potency assays using a U-937 human cell-based model validated that each batch of Thykamine™ exhibits equivalent biological activity, consistently inhibiting key inflammatory cytokines [1] Product Overview - Thykamine™, developed from Devonian's SUPREX™ platform, targets health conditions related to inflammation and oxidative stress, including ulcerative colitis and atopic dermatitis [1] - The product's anti-inflammatory, anti-oxidative, and immunomodulatory properties have been supported by numerous in vitro and in vivo studies [1] Company Background - Devonian Health Group Inc. is a clinical-stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory diseases [1] - The company also develops high-value cosmeceutical products and operates a commercialization subsidiary, Altius Healthcare LP, for selling prescription pharmaceuticals in Canada [1]

In the past few years lax protection of trademarks and patents has become a growing problem for the many Chinese companies that have emerged as IP powerhouses in their own right https://t.co/fHqkOfxHXf ...

Core Viewpoint - NeuroSense Therapeutics has strengthened its global intellectual property portfolio for its lead drug candidate PrimeC by securing an Australian patent, which complements an existing U.S. patent and extends exclusivity through October 2042 [1][2][3]. Group 1: Intellectual Property and Patent Strategy - The Australian Patent Office granted Australian Patent No. 2022370513 for PrimeC, which is a significant addition to NeuroSense's global patent protection strategy [1][2]. - The granted patent in Australia follows the approval of the corresponding U.S. patent (12,097,185), enhancing NeuroSense's exclusivity strategy for PrimeC across key global markets [2][3]. - CEO Alon Ben-Noon emphasized that securing patent protection in Australia is crucial for executing the company's global IP protection strategy for PrimeC, which is essential for long-term value creation [3]. Group 2: Product Development and Clinical Readiness - PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib, designed to target multiple disease pathways implicated in ALS and Alzheimer's disease [3][7]. - The formulation of PrimeC allows for consistent exposure across various disease pathways, supporting a multi-target disease-modifying approach [3]. - PrimeC is now Phase 3-ready in ALS, following positive results from the Phase 2b PARADIGM trial and FDA clearance of the pivotal Phase 3 protocol [4]. Group 3: Market Context and Unmet Medical Needs - Neurodegenerative diseases, including ALS and Alzheimer's, represent significant unmet medical needs, with limited effective therapeutic options currently available [5]. - ALS affects over 5,000 people annually in the U.S., with a substantial disease burden estimated at $1 billion per year [8]. - Alzheimer's disease impacts more than 30 million people globally, characterized by memory loss and cognitive decline, with a pressing need for disease-modifying treatments [10].